Antifungal agents in hematopoietic stem cell transplantation

Area of Science:

• Hematology
• Infectious Diseases
• Oncology

Background:

• Invasive fungal infections (IFIs) are a significant cause of morbidity and mortality in stem cell transplant (SCT) recipients.
• Allogeneic SCT recipients have a higher risk of IFIs compared to autologous SCT recipients.
• While fluconazole prophylaxis reduced invasive candidiasis, mold infections remain a major threat during immunosuppression for graft-versus-host disease.

Purpose of the Study:

• To review current strategies for preventing and treating invasive fungal infections in SCT recipients.
• To highlight advancements in antifungal prophylaxis and therapy.
• To discuss emerging approaches for managing IFIs in immunocompromised patients.

Main Methods:

• Review of recent clinical trials and guidelines on antifungal prophylaxis and treatment in SCT.
• Analysis of the efficacy of posaconazole prophylaxis in high-risk patients.
• Evaluation of new antifungal agents and combination therapies.

Main Results:

• Posaconazole prophylaxis is effective in preventing IFIs and reducing mortality in high-risk SCT patients.
• Preemptive strategies using biomarkers and CT scans show promise but require clinical validation.
• New antifungal agents offer improved safety and broader spectrum activity, with voriconazole as standard for invasive aspergillosis.

Conclusions:

• Fungal infection management in SCT requires tailored prophylaxis and treatment strategies.
• Advances in antifungal agents and combination therapies are crucial for improving outcomes.
• Continued research is needed to validate new diagnostic and therapeutic approaches for IFIs in SCT.